4.7 Review

Dipeptidyl peptidase 4 inhibitors: Applications in innate immunity?

期刊

BIOCHEMICAL PHARMACOLOGY
卷 188, 期 -, 页码 -

出版社

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bcp.2021.114517

关键词

Dipeptidyl peptidase; DPP4 inhibitor; Sitagliptin; Immunity; Innate immunity; Neutrophil; Macrophage

向作者/读者索取更多资源

DPP-4 inhibitors are small molecule inhibitors that prolong the insulinotropic activity of GLP-1 and are highly effective for treating Type-2 diabetes. Recent evidence suggests that DPP-4 inhibitors may also have immunomodulatory effects, particularly on aspects of innate immunity. Further research on the use of DPP-4 inhibitors in the context of the COVID-19 pandemic is highlighted.
Dipeptidyl peptidase (DPP)-4 inhibitors are a class of orally available, small molecule inhibitors that prolong the insulinotropic activity of the incretin hormone glucagon-like peptide-1 (GLP-1) and are highly effective for the treatment of Type-2 diabetes. DPP4 can also cleave several immunoregulatory peptides including chemokines. Emerging evidence continues to implicate DPP4 inhibitors as immunomodulators, with recent findings suggesting DPP4 inhibitors modify specific aspects of innate immunity. This review summarises recent insights into how DPP4 inhibitors could be implicated in endothelial, neutrophil and monocyte/macrophage mediated immunity. Additionally, this review highlights additional avenues of research with DPP4 inhibitors in the context of the COVID-19 pandemic.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据